Crinetics Pharmaceuticals Stock Buy Hold or Sell Recommendation
| CRNX Stock | USD 34.47 0.57 1.63% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Crinetics Pharmaceuticals is 'Cautious Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Crinetics Pharmaceuticals given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Crinetics Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Crinetics Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide. In addition, we conduct extensive research on individual companies such as Crinetics and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Crinetics Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Crinetics |
Execute Crinetics Pharmaceuticals Buy or Sell Advice
The Crinetics recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Crinetics Pharmaceuticals. Macroaxis does not own or have any residual interests in Crinetics Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Crinetics Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Crinetics Pharmaceuticals Trading Alerts and Improvement Suggestions
| Crinetics Pharmaceuticals generated a negative expected return over the last 90 days | |
| Crinetics Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 1.04 M. Net Loss for the year was (298.41 M) with loss before overhead, payroll, taxes, and interest of (239.12 M). | |
| Crinetics Pharmaceuticals currently holds about 408.51 M in cash with (225.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.6. | |
| Crinetics Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Acquisition by Tobin Schilke of 52000 shares of Crinetics Pharmaceuticals subject to Rule 16b-3 |
Crinetics Pharmaceuticals Returns Distribution Density
The distribution of Crinetics Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Crinetics Pharmaceuticals' future price movements. The chart of the probability distribution of Crinetics Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Crinetics Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Crinetics Pharmaceuticals returns is essential to provide solid investment advice for Crinetics Pharmaceuticals.
| Mean Return | -0.74 | Value At Risk | -7.53 | Potential Upside | 3.78 | Standard Deviation | 3.72 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Crinetics Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Crinetics Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Crinetics Pharmaceuticals, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Crinetics Pharmaceuticals back and forth among themselves.
| Shares | Jennison Associates Llc | 2024-12-31 | 2.7 M | Geode Capital Management, Llc | 2024-12-31 | 2.1 M | Paradigm Biocapital Advisors Lp | 2024-12-31 | 1.9 M | Siren, L.l.c. | 2024-12-31 | 1.6 M | Franklin Resources Inc | 2024-12-31 | 1.6 M | T. Rowe Price Investment Management,inc. | 2024-12-31 | 1 M | Cormorant Asset Management, Llc | 2024-12-31 | 1000 K | Orbimed Advisors, Llc | 2024-12-31 | 999 K | Novo A/s | 2024-12-31 | 960.2 K | Vanguard Group Inc | 2024-12-31 | 9.1 M | Fmr Inc | 2024-12-31 | 8.9 M |
Crinetics Pharmaceuticals Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | 217K | (56.5M) | (174.0M) | (200.4M) | (574.8M) | (546.1M) | |
| Change In Cash | 52.8M | 107.6M | (167.2M) | 22.2M | 209.6M | 220.1M | |
| Free Cash Flow | (62.2M) | (89.0M) | (116.9M) | (171.0M) | (229.8M) | (218.3M) | |
| Depreciation | 948K | 922K | 983K | 1.1M | 2.8M | 2.9M | |
| Other Non Cash Items | 261K | (739K) | 850K | 26.6M | (11.4M) | (10.8M) | |
| Capital Expenditures | 186K | 436K | 1.7M | 4.7M | 3.8M | 4.0M | |
| Net Income | (73.8M) | (107.6M) | (163.9M) | (214.5M) | (298.4M) | (283.5M) | |
| End Period Cash Flow | 93.6M | 201.2M | 34.0M | 56.2M | 265.8M | 279.1M | |
| Change To Netincome | 6.3M | 10.5M | 17.0M | 29.1M | 33.5M | 35.2M |
Crinetics Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Crinetics Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Crinetics Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Crinetics stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.66 | |
β | Beta against Dow Jones | 0.76 | |
σ | Overall volatility | 3.63 | |
Ir | Information ratio | -0.17 |
Crinetics Pharmaceuticals Volatility Alert
Crinetics Pharmaceuticals exhibits very low volatility with skewness of -1.27 and kurtosis of 3.85. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Crinetics Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Crinetics Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Crinetics Pharmaceuticals Fundamentals Vs Peers
Comparing Crinetics Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Crinetics Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Crinetics Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Crinetics Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Crinetics Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Crinetics Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Crinetics Pharmaceuticals to competition |
| Fundamentals | Crinetics Pharmaceuticals | Peer Average |
| Return On Equity | -0.32 | -0.31 |
| Return On Asset | -0.2 | -0.14 |
| Operating Margin | (326.13) % | (5.51) % |
| Current Valuation | 1.91 B | 16.62 B |
| Shares Outstanding | 93.05 M | 571.82 M |
| Shares Owned By Insiders | 2.08 % | 10.09 % |
| Shares Owned By Institutions | 98.00 % | 39.21 % |
| Number Of Shares Shorted | 7.8 M | 4.71 M |
| Price To Earning | (12.03) X | 28.72 X |
| Price To Book | 2.42 X | 9.51 X |
| Price To Sales | 3,087 X | 11.42 X |
| Revenue | 1.04 M | 9.43 B |
| Gross Profit | (239.12 M) | 27.38 B |
| EBITDA | (338.85 M) | 3.9 B |
| Net Income | (298.41 M) | 570.98 M |
| Cash And Equivalents | 408.51 M | 2.7 B |
| Cash Per Share | 7.60 X | 5.01 X |
| Total Debt | 51.72 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 15.94 X | 2.16 X |
| Book Value Per Share | 14.26 X | 1.93 K |
| Cash Flow From Operations | (225.97 M) | 971.22 M |
| Short Ratio | 9.13 X | 4.00 X |
| Earnings Per Share | (3.69) X | 3.12 X |
| Target Price | 75.64 | |
| Number Of Employees | 437 | 18.84 K |
| Beta | 0.58 | -0.15 |
| Market Capitalization | 3.21 B | 19.03 B |
| Total Asset | 1.43 B | 29.47 B |
| Retained Earnings | (952.11 M) | 9.33 B |
| Working Capital | 1.32 B | 1.48 B |
| Current Asset | 44.96 M | 9.34 B |
| Current Liabilities | 2.41 M | 7.9 B |
Note: Disposition of 350 shares by Struthers Richard Scott of Crinetics Pharmaceuticals subject to Rule 16b-3 [view details]
Crinetics Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Crinetics . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Crinetics Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Crinetics Pharmaceuticals? Buying financial instruments such as Crinetics Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Crinetics Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Monster Funds Thematic Idea Now
Monster Funds
Solid funds with above average long term performance indicators based on Macroaxis rating system. The Monster Funds theme has 33 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Monster Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.